{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-233039","form_type":"8-K","ticker":null,"cik":"0001183765","company_name":"Molecular Templates, Inc.","filed_at":"2024-10-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:07.862354+00:00","generated_at":"2026-05-30T19:49:29.956440+00:00","sec_items":["2.05"],"event_type":"other_material","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Molecular Templates cuts 60% of workforce (19 employees) to extend cash runway","bullets":["Board approved reduction in force of 19 employees, approximately 60% of total workforce, on Oct 3, 2024.","Company expects negligible costs from the layoffs, primarily legal and termination fees.","Implementation expected to be substantially complete in October 2024.","Company continues to evaluate strategic alternatives, including potential sale or merger."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-233039","json":"https://secwatch.observer/filing/0001193125-24-233039.json","markdown":"https://secwatch.observer/filing/0001193125-24-233039.md","text":"https://secwatch.observer/filing/0001193125-24-233039.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1183765/000119312524233039/0001193125-24-233039-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1183765/000119312524233039/d884306d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T19:49:29.956440+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"f93c37c8b95a9bf228216bc37af1db546ed38efc","claim":"Molecular Templates, Inc. announced a restructuring with charges of a negligible amount (19 employees (approximately 60% of the Company’s employees)).","evidence_excerpt":"On October 3, 2024, the Board approved a reduction in force of 19 employees (approximately 60% of the Company’s employees), in order to extend its resources and allow the Company to continue to support its clinical studies and its efforts to maximize the value of the business and its assets. The Company estimates that it will incur a negligible amount of costs in connection with the reduction in force, primarily consisting of legal fees and other related termination costs.","evidence_source":"SEC 8-K Item 2.05/2.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1183765/000119312524233039/0001193125-24-233039-index.htm","confidence":0.9,"family_label":"Restructurings & Charges","details":[{"label":"Type","value":"restructuring"},{"label":"Charge","value":"a negligible amount"},{"label":"Headcount","value":"19 employees (approximately 60% of the Company’s employees)"}],"fact_type":"restructuring_charge"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}